



**Neovacs, a biotechnology company,  
selected for the 2006 Red Herring 100 Europe**

Neovacs is recognized as one of the most promising biotechnology companies  
in Europe and Israel

**Paris, May 9 2006** - Neovacs, ([www.neovacs.com](http://www.neovacs.com)), a world-leading biotechnology company developing anti-cytokine and anti viral regulatory proteins vaccines, is pleased to announce that it has been selected as one of the 100 companies driving the future of technology in the EMEA region by Red Herring in its prestigious “Red Herring100 Europe” listing. The company will present at the Venture Market Europe 2006 conference on May 10 at 5:30 p.m. (Hotel Westin Castiglione, Paris).

Since its foundation in 1993, Neovacs has built an impressive portfolio of drug candidates in AIDS, Cancers, Auto-Immunity and Allergy. Today, in industrial collaboration with Sanofi Pasteur, Neovacs is initiating a phase I/II clinical trial for one of its first products, Tat toxoid, in the indication of AIDS, and collaborates with Debiopharm for the development of an anti-TNF alpha whose potential indications include cancer cachexia and autoimmune diseases. In addition, Neovacs counts additional in-house products that will enter in clinical phase within the next 18 to 24 months.

"Neovacs is very proud of the Red Herring's recognition that puts it among the 100 leading private companies in innovation and technology", said Alain Huriez MD, CEO, Neovacs. "It not only validates our business model and the collaborations we signed with Sanofi Pasteur and Debiopharm with regards to two of our products, but also our very active in-house R&D that is driving several products in preclinical development phase".

"Market obstacles remain but our list shows that great companies are being created in Europe," said Red Herring editor-in-chief Joel Dreyfuss.

Red Herring's lists of top private companies are an important part of the magazine's tradition of identifying new and innovative technology companies and entrepreneurs. Companies like Google, eBay and Skype were spotted in their early days by Red Herring editors as those that would change the way we live and work.

Red Herring's editorial staff rigorously evaluated more than 700 private companies through a careful analysis of financial data and subjective criteria, including quality of management, execution of strategy, and dedication to research and development.

### **About Neovacs**

Neovacs is a worldwide pioneer in therapeutic vaccines against human cytokines (Kinoids) and immunosuppressive viral proteins (Toxoids). Neovacs was founded in 1993 by Professor Daniel Zagury, M.D., as a spin-off from Pierre and Marie Curie University, Paris. Neovacs has invested more than €20 million in R&D since its inception, has been supported by ANVAR, holds 16 broad patents covering its Toxoid et Kinoid technologies and develops several drug candidates to treat AIDS, Cancer, and Auto-Immune diseases. Neovacs signed a development and licensing agreement with Sanofi Pasteur for one of its first promising products, Tat Toxoid, a leading candidate for treatment of AIDS, as well as with Debiopharm for the development of a TNF alpha kinoid for potential indications such as cancer cachexia and autoimmune diseases.

For more information on Neovacs, please visit our website at [www.neovacs.com](http://www.neovacs.com)

### **About Red Herring**

Red Herring, Inc., founded in 1993, is a media company whose mission is to cover innovation, technology, financing and entrepreneurial activity. Its staff of award-winning journalists tell readers what's first, what matters and most importantly, why.

Red Herring is dedicated to thorough research, relevant metrics deep financial analysis, in-depth reporting, crisp writing and thoughtful debate. We are a skeptical, intelligent and trustworthy source of information in technology business. Our primary obligation is to provide the most relevant, honest and independent information and analysis to our audience, with the conviction that an exceptional editorial product is the best catalyst for success and the best way to serve our advertisers and investors. Our content is original, compelling and actionable for industry executives and entrepreneurs.

A privately held company, Red Herring, Inc. is headquartered in Belmont, California. For more information visit [www.redherring.com](http://www.redherring.com)

# # #

*This press release may contain forward-looking statements. As such, they do not guarantee future performance; there are risks and uncertainties. Future scientific, preclinical, clinical, regulatory, manufacturing, financial, commercial, business outcomes may be substantially different from those suggested by the forward-looking statements. The forward-looking statements are effective only as per the date at the top of this press release.*

### **Press and analyst contact:**

Alizé PR

Caroline Carmagnol

33 (0) 6 64 18 99 59

caroline.carmagnol@wanadoo.fr

NEOVACS -- contact@Neovacs.com